SCHEMBL3225929

SCHEMBL3225929

CN1CCN(c2ccc3ccccc3c2)c2ccc(-c3ccc(OC(F)F)nn3)cc2C1

nearest known ligand 0.43

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 9/20 0.43
SLC6A2 P23975 5/20 0.41
SLC6A3 Q01959 5/20 0.41
SLC6A4 P31645 4/20 0.41
HTR3A P46098 1/20 0.37
KDM4E B2RXH2 1/20 0.35
NPC1 O15118 1/20 0.35
MAPT P10636 1/20 0.35
XBP1 P17861 1/20 0.35
RAB9A P51151 1/20 0.35
KLF5 Q13887 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HTR6 P50406 1/20 0.32
RAD52 P43351 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3235932 0.90 SCN9A (0.44) SCN9ASLC6A2SLC6A3SLC6A4NPC1
SCHEMBL3235642 0.87 SLC6A2 (0.47) SCN9ASLC6A2SLC6A3SLC6A4HTR6
SCHEMBL3230792 0.87 SCN9A (0.44) SCN9ASLC6A2SLC6A3SLC6A4
SCHEMBL3227672 0.86 SCN9A (0.42) SCN9ASLC6A2SLC6A3SLC6A4
SCHEMBL3235921 0.86 SCN9A (0.45) SCN9ASLC6A2SLC6A3SLC6A4HTR3A
SCHEMBL3234936 0.86 SLC6A2 (0.53) SCN9ASLC6A2SLC6A3SLC6A4NPC1
SCHEMBL3223220 0.85 SLC6A2 (0.47) SCN9ASLC6A2SLC6A3SLC6A4NPC1
SCHEMBL3227282 0.84 SLC6A2 (0.42) SCN9ASLC6A2SLC6A3SLC6A4
SCHEMBL3225653 0.84 SCN9A (0.46) SCN9ASLC6A2SLC6A3SLC6A4HTR3A
SCHEMBL3234471 0.84 SLC6A2 (0.57) SCN9ASLC6A2SLC6A3SLC6A4HTR3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096546-B2 Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin ALBANY MOLECULAR RESEARCH, INC. (US) 2015-08-04 US disclosed
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ALBANY MOLECULAR RESEARCH, INC. (US) 2010-06-03 US disclosed
EP-2146722-A1 ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN AMR Technology, Inc. (US) 2010-01-27 EP disclosed
WO-2008141081-A1 ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN AMR TECHNOLOGY, INC. (US) 2008-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ADRA1B, ADRB1, ADRA1D SCN9A 795/4885SLC6A2 28/4885SLC6A3 32/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.